Opthea Limited (AU:OPT) has released an update.
Opthea Limited, a company focused on developing treatments for retinal diseases, acknowledged an error in their financial reporting and announced the completion of a significant funding round, raising A$227.3 million. The company also reported progress in their key Phase 3 trials for a novel wet AMD therapy, with topline data expected in 2025. Additionally, the company has made strategic leadership appointments to bolster its medical affairs and board expertise.
For further insights into AU:OPT stock, check out TipRanks’ Stock Analysis page.
